Detection Technology - Outlook has slightly deteriorated
DT releases its Q3 result on Wednesday, 26th of Oct. With weakened macroeconomic outlook and increased cost pressures, we adjusted our short-term estimates but still expect DT to deliver solid growth in coming years.
Growth is expected to continue in Q3 and H2
After the soft quarter of Q2, we expect DT to deliver double-digit topline growth both in Q3 and H2. With delayed Q2 net sales (due to supply chain issues), we expect MBU to grow by 16.4% y/y in Q3. Our SBU’s Q3 growth estimate of 24.7% is supported by a favorable market trend after a weak performance during the pandemic times. IBU had a strong comparison period (Q3’21: EUR 3.8m) and thus we expect the BU to grow only by 2.4% y/y. Our Q3 group net sales estimate amounts to EUR 27.1m, reflecting 16.8% y/y growth. In total, we expect DT to grow by 9.8% to EUR 98.6m in 2022.
Margins are under short-term pressure
Due to reduced topline estimates and cost inflation, we expect Q3 EBIT to land at EUR 3.8m (13.9% margin). Elevated material costs and higher investment in R&D cause some stress on Q3 and H2 margins. Our 2022 EBIT estimate of EUR 9.7m (9.9% margin) is quite moderate against DT’s margin potential and those seen in the past. We expect margins to significantly improve in 2023 when component availability improves and extraordinary R&D investments are over.
Outlook for security is favorable, medical growth to calm
Security market has performed well in 2022 and the demand outlook is bright. Major countries are investing in infrastructure security, aviation being one of the largest contributors. Both the company’s management and OEMs have indicated that the growth in the medical markets might be slowing down. However, we expect MBU to grow also in the future, at or above long-term the market.
Valuation neutral ahead of Q3, but risks are elevated
Our 23 EBIT estimate was decreased by some 17% due to elevated risk levels. With the recent decline in DT’s share price, 23E valuation seems quite neutral (23E EV/EBIT of 14x and P/E of 20x). We, however, don’t see much upside potential in multiples given weakening economic and industrial activity. We retain our HOLD-rating but lower TP to EUR 17.0 (20.0) ahead of Q3 result.
After the soft quarter of Q2, we expect DT to deliver double-digit topline growth both in Q3 and H2. With delayed Q2 net sales (due to supply chain issues), we expect MBU to grow by 16.4% y/y in Q3. Our SBU’s Q3 growth estimate of 24.7% is supported by a favorable market trend after a weak performance during the pandemic times. IBU had a strong comparison period (Q3’21: EUR 3.8m) and thus we expect the BU to grow only by 2.4% y/y. Our Q3 group net sales estimate amounts to EUR 27.1m, reflecting 16.8% y/y growth. In total, we expect DT to grow by 9.8% to EUR 98.6m in 2022.
Margins are under short-term pressure
Due to reduced topline estimates and cost inflation, we expect Q3 EBIT to land at EUR 3.8m (13.9% margin). Elevated material costs and higher investment in R&D cause some stress on Q3 and H2 margins. Our 2022 EBIT estimate of EUR 9.7m (9.9% margin) is quite moderate against DT’s margin potential and those seen in the past. We expect margins to significantly improve in 2023 when component availability improves and extraordinary R&D investments are over.
Outlook for security is favorable, medical growth to calm
Security market has performed well in 2022 and the demand outlook is bright. Major countries are investing in infrastructure security, aviation being one of the largest contributors. Both the company’s management and OEMs have indicated that the growth in the medical markets might be slowing down. However, we expect MBU to grow also in the future, at or above long-term the market.
Valuation neutral ahead of Q3, but risks are elevated
Our 23 EBIT estimate was decreased by some 17% due to elevated risk levels. With the recent decline in DT’s share price, 23E valuation seems quite neutral (23E EV/EBIT of 14x and P/E of 20x). We, however, don’t see much upside potential in multiples given weakening economic and industrial activity. We retain our HOLD-rating but lower TP to EUR 17.0 (20.0) ahead of Q3 result.